English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
- AN2 Therapeutics press release (NASDAQ:ANTX): Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year.
- R&D expenses for the full year 2023 were $54.9 million, compared to $29.5 million in the prior year.
- The company had cash, cash equivalents, and investments of $134.5 million at December 31, 2023.
Read the full article here
